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Abstract
Background: Controlled clinical trials have shown that a six-dose regimen of artemether-lumefantrine (AL) therapy
for uncomplicated Plasmodium falciparum malaria results in cure rates >95% with good tolerability.
Materials and methods: A prospective study was carried out to document the adherence to and acceptability of
AL administration. This was undertaken in the context of the ALIVE study, a prospective, community-based,
observational study in a rural, malaria-endemic area of Tanzania. Following microscopic confirmation of P.
falciparum infection, the first AL dose was taken under supervision, with the subsequent five doses taken
unsupervised at home. Patients were randomized to receive a home-based assessment close to the scheduled
time for one of the unsupervised doses, but were blinded to which follow-up visit they had been allocated. A
structured questionnaire was administered by trained staff and AL consumption was confirmed by inspection of
blister packs.
Results: A total of 552 patients were recruited of whom 352 (63.8%) were <13 years old. The randomization
process allocated 112, 109, 110, 100 and 111 patients to a follow-up visit after doses 2, 3, 4, 5 and 6, respectively.
For dose 2, 92.0% of patients (103/112) correctly took AL at 8 ± 1 hours after dose 1. The remaining doses were
taken within four hours of the correct time in 87-95% of cases. Nine patients (1.7%) missed one dose. Blister packs
were available for inspection in 548 of cases (99.3%) and confirmed patient-reported data that the previous dose
had been administered. Nearly all patients took AL with water (549/552 [99.5%]). Two patients (0.4%) took the drug
with food. The dosing pictogram and clustering of tablets within the blister packs was considered helpful by 91.8%
and 100.0% of patients, respectively. Overall, 87.1% of patients (481/552) found AL easier to take/administer than
sulphadoxine-pyrimethamine (SP) and 87.7% (484/552) believed that AL was more effective than SP.
Discussion: Factors contributing to adherence were likely to be helpful packaging, pictorial dosing instructions and
patients’ conviction that AL is effective.
Conclusion: Adherence to the dosing regimen and timing of AL administration was very good.
Background
Malaria is the leading cause of outpatient and inpatient
admissions in most sub-Saharan African countries,
including Tanzania, and continues to exert a high bur-
den in terms of mortality [1-3], morbidity [1,4] and
health expenditure [5,6]. The use of anti-malarial drugs
for chemotherapy and chemoprophylaxis is a critical
component in the fight against malaria, but Plasmodium
falciparum resistance to conventional anti-malarials,
such as chloroquine and sulphadoxine-pyrimethamine
(SP), is high [1,7-10]. It is for this reason that the World
Health Organization (WHO) has been recommending
artemisinin-based combination therapy (ACT) as first-
line therapy to replace failing anti-malarial drugs [11].
The ACT artemether-lumefantrine (AL, Coartem®)
combines the short-acting artemisinin derivative arte-
mether with long-acting lumefantrine. Giving the second
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achieves and maintains the blood concentration of arte-
mether above the minimum effective concentration [12]
to help ensure that malaria parasites are exposed to
high levels during the middle third of their life cycle,
when they are most susceptible to anti-malarial agents
[13]. AL has demonstrated a high level of efficacy and a
good tolerability profile [14-18]. As a result, the national
treatment policy of Tanzania was revised in November
2006 to adopt AL as first-line treatment for uncompli-
cated malaria.
AL is administered as a six-dose regimen over a per-
iod of three days [19]. Controlled trials using this regi-
men have demonstrated cure rates of over 95% [20-23],
consistent with recommendations from WHO that cure
rates for uncomplicated P. falciparum malaria should be
at least 90% and preferably exceed 95% [11]. Evidence
regarding the adherence to the AL dosing regimen and
feasibility of its use in programmatic conditions remains
limited [24-29]. Nevertheless, proper evaluation of
adherence and acceptance outside the context of con-
trolled clinical studies is important as AL is widely
deployed throughout malaria endemic sub-Saharan
countries.
Following the inclusion of AL within the national
Tanzanian treatment policy, the ALIVE (’artemether-
lumefantrine in vulnerable patients: exploring health
impact’)s t u d yw a su n d e r t a k e ni nar u r a l ,m a l a r i a -
e n d e m i ca r e ao ft h ec o u n t r yw i t ht h ea i mo fe v a l u a t i n g
the impact of introducing AL as first-line malaria
treatment on malaria-related morbidity and mortality.
As part of ALIVE, a prospective study was conducted
under routine conditions to document the adherence
to and acceptability of AL drug administration in this
setting.
Methods
The ALIVE study
ALIVE is a prospective, observational, community-based,
longitudinal, demographic surveillance study taking
place in two rural districts of Tanzania (Ulanga and
Kilombero). The primary objective is to assess the effect
of AL on all-cause mortality in infants and children ≥3
months of age (and >5 kg) and <5 years old, using his-
torical data based on the former first-line treatment
with SP as comparator. Secondary objectives include
assessment of adherence to the AL regimen, knowledge
of correct AL intake and patient satisfaction.
T h ec o n d u c to ft h eA L I V Es t u d yc o m p l i e sw i t ht h e
Declaration of Helsinki. The study protocol was
approved by the institutional review board of the Ifakara
Health Institute (IHI), which implements the ALIVE
study, and the Tanzanian National Institute for Medical
Research (NIMR).
Administration of AL
As per the instructions from the manufacturer (Novartis
Pharma AG, Basel, Switzerland), AL is dosed according
to body weight: 5 to <15 kg, one tablet per dose; 15 to
<25 kg, two tablets per dose; 25 to <35 kg, three tablets
per dose; ≥35 kg, four tablets per dose. The first two
doses of AL are to be given eight hours apart on day 1.
On days 2 and 3, AL is to be given twice daily, 12 hours
apart; with the morning dose being administered 24
hours after the first dose was taken.
In this study, the first dose of AL was taken under
supervision at the health facility, with the subsequent
five doses taken unsupervised at home. Dosing and time
of taking/administering the drugs was explained and the
time was clearly marked on the AL blister packs by the
dispensing healthcare provider. Patients or caregivers
were advised to ensure AL was not taken/given on an
empty stomach.
Assessment of adherence and acceptability
Assessment of adherence to and acceptability of AL was
conducted within the context of the ALIVE study and
was undertaken at the Mlimba Health Center in the
Kilombero District during the period March to April
2008, i.e. approximately one year after the new treat-
ment policy was introduced in Tanzania (January 2007).
Patients living in villages no further than six kilometers
f r o mt h eM l i m b aH e a l t hC e n t e rw e r ee l i g i b l et ot a k e
part in the assessment if they had no clinical signs of
complicated malaria and P. falciparum infection was
confirmed by blood smear. Informed consent was
obtained from all patients.
A computer-generated randomization list was used to
allocate eligible patients to a home visit for one of the
five doses of AL to be taken after the initial, supervised
dose. It was planned that all patients be visited at home
at a time close to the scheduled time of AL administra-
tion. In the event that patients were due to be visited
late in the evening or at night following an evening
dose, visits were scheduled for the following morning.
Patients or caregivers were informed that there would
be a follow-up visit but were blinded as to which of the
five possible follow-up visits they had been allocated.
Each visit was undertaken by one of two IHI field
workers or three local field assistants, after appropriate
training based on standard AL training materials pro-
vided by the drug manufacturer (Novartis) which had
been field tested by researchers from IHI in Ifakara. For
patients younger than 13 years, the patient’s caregiver
was interviewed instead of the patient.
Questionnaire
A structured questionnaire (see Additional file 1) was
developed by researchers from IHI and the Swiss
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tested by researchers from IHI in Ifakara, and then
administered to the patient or caregiver at each visit.
This included questions on the number of doses to be
administered, the number of tablets per dose, the exact
time at which the last dose was given, reason for any
missed doses, appropriate action if a dose was vomited,
consumption of concomitant food or drink at the time
of AL dosing, and how patients/caregivers remembered
that AL doses should be taken. Additional questions
included whether the instructions/drawing on the AL
pack were considered useful, how patients/caregivers
perceived the clustered doses in the blister packs, how
easy it was for them to take/administer AL, how effec-
tive they judged AL as compared to SP (the previous
first-line therapy for uncomplicated malaria in Tanza-
nia), and their preference for AL over other treatments
(antibiotics, analgesics/antipyretics, quinine injection,
herbs from traditional healer or remedy from witchdoc-
tor). Consumption of the dose was confirmed by inspec-
tion of the AL blister packs.
Results
Patient population
A total of 552 patients met the eligibility criteria and
were recruited for the study (Table 1). The majority of
patients (352/552 [63.8%]) were aged less than 13 years.
All included patients had come to the medical facility to
seek medical attention for fever. Almost all patients
(544/552, 98.6%) were reported to be unwell or moder-
ately unwell at the time of presentation to the health
facility.
The randomization process allocated 112, 109, 110,
100 and 111 patients to a follow-up visit after doses 2,
3, 4, 5 and 6, respectively.
Adherence to AL
AL was dispensed at the Mlimba Health Center in all
cases. When asked, 100% of patients/caregivers reported
that they had received an explanation of how to use AL.
Results of the questionnaire confirmed that all patients/
caregivers understood the number of doses required,
and the number of tablets that should be taken/admi-
nistered per dose (Table 2). All but one patient
responded that five doses in total were to be taken, an
answer that was correct when referring only to the
doses for which they were responsible (the first dose
was given by the healthcare provider). AL was taken at
the correct time in approximately 90% of cases for each
dose (Table 2). For dose 2, 92.0% of patients (103/112)
took AL at 8 ± 1 hours after dose 1. The remaining
doses were taken within four hours of the correct time
in 87-95% of cases. In total, nine out of 522 patients
(1.7%) reported missing a single dose of AL. In two out
of these nine cases, the patient had forgotten to take
the final dose. One patient used the intended dose to
r e p l a c ead o s ev o m i t e dp r e v i o u s l y ,a n do n ep a t i e n t
ceased to take the drug after vomiting. In the remaining
five patients there was no apparent reason for missing
prescribed doses. AL blister packs were available for
examination at the randomized visit in 548 cases
(99.3%), and the reported number of doses taken corre-
sponded with actual pill count at each visit. No patient
missed more than one dose, and no patient missed dose
2. In case of a dose being vomited, the majority of
patients correctly understood that they should return to
the health facility for a replacement dose (316/552,
57.3%). However, a relatively high proportion of patients
(42.7%) incorrectly believed that a replacement dose
could be taken from the existing blister pack or that no
action was required.
Nearly all patients took AL with water (549/552
[99.5%]). Two patients (0.4%) took the drug with food.
T h em o s tf r e q u e n t l yr e p o r t e d factor that positively
influenced adherence to the timing of AL dosing was
the impact of the current illness (Table 2).
Table 1 Patient characteristics (n = 522)
Attribute N (%)
Age
<13 years 352 (63.8)
≥13 years 200 (36.2)
Female gender 319 (57.8)
Level of education of patient/caregiver
None 63 (11.4)
Primary school 421 (76.3)
Secondary school 68 (12.3)
College 0 (0)
Occupation of patient/caregiver
Employed 22 (4.0)
Self employed 77 (13.9)
Farmer 369 (66.9)
Other 84 (15.2)
Age
3 months - 3 years 270 (48.9)
3 - 8 years 62 (11.2)
8 - 12 years 39 (7.1)
>12 years 181 (32.8)
Patient condition on presentation at health facility
Very unwell 0 (0)
Unwell 399 (72.2)
Moderately unwell 145 (26.3)
Moderately well 2 (0.4)
Well 1 (0.2)
Perfectly well 5 (0.9)
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Almost all patients (91.8%) found the dosing pictogram
helpful, and all patients reported that clustering of
tablets within the blister packs was useful (Table 3). In
total, 87.1% of patients (481/552) found AL easier to
take/administer than SP and 484/552 (87.7%) believed
that AL was more effective than SP (Table 3). Approxi-
mately 90% of patients (495/552) would not have pre-
ferred other medications than AL to treat the current
illness, although 5.6% (31 patients) would have chosen
quinine injections. Two patients would have preferred
to receive herbs from a traditional healer.
Discussion
Adherence to the standard AL regimen was very good in
this population of patients in a rural area of sub-Saharan
Africa. The full six-dose regimen was taken by 98% of
patients, with the dose being taken at a satisfactory time
in ~90% of cases. These results were obtained without
any additional training for staff at the dispensing health
center beyond the standard National Malaria Control
Programme training initiative, and no special guidance
was given to patients other than that which is routinely
offered by the local healthcare personnel. The propor-
tion of patients taking all five unsupervised doses was
consistent with other reports for ACT in general [24,25]
and AL in particular [26-29]. This is, however, the first
study to provide data related to the timing of AL admin-
istration, and the first to apply a randomized study
design to the assessment of AL adherence.
Although multiple doses of AL are required, there is
no need for individual dose calculations according to
body weight; instead, complete treatment packages are
available for each body weight group. Thus, AL is sim-
pler to prescribe than SP, the previous first-line therapy,
which requires weight-adjusted dosing. However,
patients need to take five doses of AL unsupervised over
a three-day period compared to a single dose of SP. The
findings, however, indicate that adherence to the AL
regimen is very good following standard instructions
from the dispensing healthcare provider, as confirmed
Table 2 Assessment of adherence to the AL dosing
regimen, as evaluated by questionnaire (n = 522)
N (%)
How many doses in total to be administered for a
complete course of treatment
10
20
30
40
5 551(99.8)
6 1 (0.2)
Number of tablets per dose to be taken?
1 tablet 270/270
(100)
2 tablets 62/62 (100)
3 tablets 40/40 (100)
4 tablets 180/180
(100)
AL dose taken at correct time (i.e. ± 1 hours for dose 2, ±
4 hours for doses 3-6)
Dose 2 103/112
(92.0)
Dose 3 103/109
(94.5)
Dose 4 100/110
(91.0)
Dose 5 96/110
(87.0)
Dose 6 99/111
(89.2)
Number of missed doses
Dose 2 0/122 (0)
Dose 3
a 2/109 (1.8)
Dose 4
b 2/110 (1.8)
Dose 5
c 3/100 (3.0)
Dose 6
d 2/111 (1.8)
Action to be taken if tablets are vomited
Go back to health facility for replacement dose 316 (57.3)
Give another dose 209 (37.8)
Do nothing 27 (4.9)
Don’t know 0 (0)
With what was AL taken/given?
Nothing 0 (0)
Water only 549 (99.4)
Food 2 (0.4)
Beverage 1 (0.2)
Other 0 (0)
Timing of tablet intake when administered with food?
Before meal 171 (31.0)
During meal 2 (0.4)
After meal 379 (68.6)
What acted as a reminder to take tablets?
e
The dispenser’s instructions 231 (41.8)
The pictograms 309 (55.9)
Table 2: Assessment of adherence to the AL dosing regi-
men, as evaluated by questionnaire (n = 522) (Continued)
Illness 12 (2.2)
Other
f 12 (2.2)
a Dose used to replace vomited dose 2 (n = 1), dose not taken due to stomach
ache (n = 1)
b Dose delayed (n = 1), tablets lost (n = 1)
c No reason given (n = 1), dose not taken due to excessive vomiting (n = 1),
admitted to hospital due to asthma, treated with quinine (n = 1)
d Forgot to take dose (n = 1)
e Refers to morning dose (results were similar for evening dose)
f Not specified
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patient responses to the questionnaire, the clustering of
tablets for each dose within the AL blister packets is
likely to have contributed to the correct number of
tablets being taken, and the pictogram shown on the
packaging was considered as a helpful supplement to
the instructions provided by healthcare workers. The
pictogram made the timing of drug administration clear
in this rural area where few individuals have a clock or
wrist watch [30]. Care should be taken, however, that
dispensing staff explain that the ‘sun’ and ‘moon’ sym-
bols refer to daytime and night-time, and not sunrise
and sunset as believed in a few isolated cases among the
study population. Finally, the wide-held response that
AL is effective may also have played a role in supporting
adherence to the regimen.
It was notable that responses indicated that AL was
virtually never taken with food, despite the fact that
health providers emphasized that AL works better if not
taken on an empty stomach. Based on responses to the
question about timing of tablet intake, it appears that
some patients may have eaten shortly before or after
taking the AL dose and did not consume additional
food at the time of dosing, but specific information was
not collected. It is encouraging, however, that a recent
analysis of data from a large-scale study of AL in five
African countries found that although concomitant food
intake increased lumefantrine absorption in children
with malaria, there was no tendency for lower food
intake in the few patients in whom treatment failure
was recorded [31]. Indeed, all 37 patients who were
unable to eat food with any dose achieved PCR-cor-
rected cure at day 28. Nevertheless, food consumption,
or resuming food consumption as soon as possible, at
the time of AL dosing remains advisable in order to
maximize effectiveness, in view of the observed associa-
tion between lumefantrine exposure and clinical and
parasitological outcomes [23]. This can, of course, be
challenging since initially patients may be reluctant to
eat due to symptoms of nausea and vomiting during the
acute phase of malaria.
Fewer than 60% of patients or caregivers understood
the need to return to the health clinic for a replacement
if a dose was vomited. Although the number of patients
in whom a dose was reported to have been vomited was
low (n = 2), the findings that more than 40% of patients
or caretakers did not know what to do if this happens is
of concern.
The current findings provide detailed evidence of the
timely intake of AL under programmatic conditions.
Other analyses of unsupervised adherence have all
involved home visits after the three-day course was
c o m p l e t e d[ 2 6 - 2 9 ] .E n c o u r a g i n g l y ,h o w e v e r ,n os t u d y
has reported fewer than 90% of patients taking all six
doses by the end of the three-day treatment period,
based on pill counts. In this case, it was possible to vali-
date oral information about pill administration in over
99% of cases, and found no difference between reported
consumption and the remaining number of pills. Such
validation is essential given the known limitations of
self-reporting [32]. The findings of this study concur
with those described recently by Bell et al,b a s e do na
study in Malawi in which children or adults with
uncomplicated P. falciparum m a l a r i aw e r er a n d o m i z e d
to receive AL or chorproguanil-dapsone [29]. Of the
patients randomized to receive AL, 100% reported cor-
rect pill consumption during oral interviews. However,
Table 3 Acceptability assessments (n = 552)
N (%)
Were the instructions (drawings) in the AL pack useful?
Yes 507 (91.8)
No 34 (6.2)
Don’t know 11 (2.0)
Was the clustering of AL doses useful to remember how to
take the drug?
Helpful 552 (100)
Confusing 0 (0)
Not important 0 (0)
How do you or your child feel now?
Very unwell 6 (1.1)
Unwell 5 (0.9)
Moderately unwell 3 (0.6)
Moderately well 47 (8.5)
Well 486 (88.0)
Perfectly well 9 (0.9)
How do you find AL to administer/take?
Easier to take than SP 481 (87.1)
Less easy than SP 2 (0.4)
Same as SP 32 (5.8)
Don’t know 37 (6.7)
Do you find that AL works?
Yes 549 (99.5)
Better than SP 484 (87.7)
Same as SP 32 (5.8)
Don’t know 35 (6.5)
No 3 (0.6)
Would you or your child prefer to have anything else than
AL for this particular illness?
No 495 (89.7)
Yes 57 (10.3)
No specific choice 21/57(36.8)
Antibiotics 1/57 (1.8)
Analgesics/antipyretics 2/57 (3.5)
Quinine injection 31/57
(54.4)
Herbs from traditional healer 2/57 (3.5)
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dispensed from an electronic pill container that
recorded the time of opening, Bell et al found that the
rate of adherence was only 92%. Thus, the adherence
rate obtained using this different measurement approach
was the same as that observed in this study population
(92%), where we assessed adherence by randomized,
scheduled visits shortly after each dose was due to be
taken. Clinically, the high adherence rates observed
when AL is self-administered after the first dose have
been shown to result in excellent efficacy rates irrespec-
tive of whether the drug is given supervised or unsuper-
vised [23].
Certain aspects of the study design merit considera-
tion. The study was undertaken in the context of rou-
tine use of AL therapy in a rural area of sub-Saharan
Africa. The healthcare providers who dispensed AL did
not receive any special training in addition to the stan-
dard training provided through the National Malaria
Control Programme, when first-line treatment with AL
was introduced, approximately one year prior to this
assessment. Also, the randomization approach helped
ensure comparability of groups for each AL dose
assessed, and minimized the influence of interviews by
avoiding expected or repeated visits. However, we are
aware that responses may be due to the phenomenon
that patients or caregivers provided answers they
thought would be expected or desired by the inter-
viewer. Whether or not a pill had been removed from
the blister pack could be checked through pill counts,
but other questions - e.g. those in which the acceptabil-
ity of AL was compared to other treatment options -
could not be validated. Furthermore, responses for chil-
dren under 13 years were given by parents or caregivers,
not by the patient. Therefore, the views expressed in
cases of children under 13 are those of their parents/
guardians and may not necessarily reflect the patient’s
perspective. We also recognize that the questions posed
could be refined, particularly those which resulted in
100% or near-100% responses, such as ‘Was the cluster-
ing of AL doses useful to remember how to take the
drug?’. Moreover, there is a need to standardize ques-
tionnaires that assess adherence and acceptability to
improve the quality and subtlety of the information
gained and to improve comparability between studies.
In conclusion, adherence to the AL regimen as stan-
dard first-line treatment of uncomplicated P. falciparum
malaria was high among this rural study population.
Patients adhered closely to the dosing regimen, partly
due to effective packaging and pictorial dosing instruc-
tions and to patients’ conviction that AL is effective.
These results may be helpful for future training of
healthcare providers by National Malaria Control Pro-
grammes in sub-Saharan Africa before and during
implementation of ACT therapy as first-line anti-malar-
ial treatment.
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